\nPrin aceast\u0103 achizi\u0163ie, Pfizer \u00ee\u015fi propune s\u0103-\u015fi extind\u0103 portofoliul \u015fi s\u0103 intre pe pia\u0163a imens\u0103 \u015fi \u00een cre\u015ftere a medicamentelor pentru tratarea obezit\u0103\u0163ii, noteaz\u0103 AFP.<\/p>\n
\nTranzac\u0163ia prevede plata a 47,50 dolari pe ac\u0163iune \u00een numerar la \u00eenchidere, plus drepturi de valoare contingent\u0103 care ar putea aduce p\u00e2n\u0103 la 22,50 dolari suplimentari pe ac\u0163iune, legate de atingerea anumitor obiective clinice \u015fi de reglementare, potrivit Business Wire.<\/p>\n
\n\u201eObezitatea este un domeniu vast \u015fi \u00een cre\u015ftere, cu peste 200 de afec\u0163iuni asociate”, a declarat Albert Bourla, pre\u015fedintele \u015fi CEO-ul Pfizer.<\/p>\n
\nAchizi\u0163ia \u201epropulseaz\u0103 Pfizer \u00een acest domeniu terapeutic cheie\u201d, a ad\u0103ugat el.<\/p>\n
\nMetsera, fondat\u0103 \u00een 2022 cu sediul \u00een New York, dezvolt\u0103 medicamente pentru obezitate \u015fi boli cardiometabolice.<\/p>\n
\nCompania are \u00een portofoliu candida\u0163i terapeutici pentru tratamente injectabile s\u0103pt\u0103m\u00e2nale \u015fi lunare, inclusiv MET-097i, un agonist al receptorului GLP-1 aflat \u00een faza 2 de dezvoltare, \u015fi MET-233i, un candidat analog al amilinei lunar \u00een faza 1.<\/p>\n
\n\u201eDe la \u00eenfiin\u0163are, Metsera a lucrat pentru a reduce povara fizic\u0103, emo\u0163ional\u0103 \u015fi economic\u0103 a obezit\u0103\u0163ii”, a declarat Whit Bernard, cofondator \u015fi CEO al Metsera. El a subliniat c\u0103 portofoliul companiei “promite s\u0103 transforme poten\u0163ial vie\u0163ile a sute de milioane de oameni”.<\/p>\n
\nTranzac\u0163ia se preconizeaz\u0103 a fi finalizat\u0103 \u00een al patrulea trimestru al anului 2025, sub rezerva aprob\u0103rilor reglementare \u015fi ale ac\u0163ionarilor Metsera. Consiliile de administra\u0163ie ale ambelor companii au aprobat \u00een unanimitate acordul.<\/p>\n
\nAchizi\u0163ia permite Pfizer s\u0103 concureze pe pia\u0163a medicamentelor pentru obezitate, dominat\u0103 \u00een prezent de companii precum Novo Nordisk \u015fi Eli Lilly cu produsele lor Ozempic \u015fi Mounjaro.<\/p>\n","protected":false},"excerpt":{"rendered":"
Gigantul farmaceutic american Pfizer va cump\u0103ra Metsera, un produc\u0103tor de medicamente pentru obezitate \u015fi boli de inim\u0103, pentru 4,9 miliarde de dolari, au anun\u0163at luni cele dou\u0103 companii.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[170,61347,10429],"class_list":["post-240502","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-achizitie","tag-metsera","tag-pfizer"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/240502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=240502"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/240502\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=240502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=240502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=240502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}